The Future of Precision: Focal Boosting in Prostate Cancer Radiotherapy
The European Society for Radiotherapy and Oncology (ESTRO) has released new clinical practice consensus recommendations for focal boosting in prostate cancer radiotherapy. By selectively increasing radiation doses to dominant intraprostatic lesions while maintaining standard dosing for the rest of the gland, oncologists can improve biochemical progression-free survival for high-risk patients without significantly increasing treatment-related toxicity, according to the consensus paper authored by T. Willigenburg and colleagues.
Why Shift Toward Focal Boosting?
Prostate cancer recurrences frequently emerge at the location of the original, dominant tumor. Traditional whole-gland dose escalation has successfully improved outcomes, but it carries a higher risk of urinary and gastrointestinal side effects by exposing healthy tissue to intense radiation, according to the ESTRO consensus. Focal boosting targets the cancer burden directly, prioritizing the protection of the urethra, bladder, and rectum.
The phase III FLAME trial, which serves as the cornerstone for these recommendations, showed a 10-year biochemical progression-free survival rate of 86% for patients receiving a focal boost, compared to 71% for those receiving standard-of-care radiation.
What Does the Evidence Say?
The FLAME trial remains the definitive study on this treatment strategy. In a cohort of 571 men with intermediate- and high-risk disease, researchers delivered 77 Gy to the whole prostate, with the focal boost arm receiving up to 95 Gy to the gross tumor volume. According to the data, the focal boost did not result in a significant increase in acute or late toxicity when clinicians strictly adhered to organ-at-risk dose constraints.
Which Patients Benefit Most?
The ESTRO experts suggest that focal boosting is most effective for men with unfavorable intermediate-risk, high-risk, and very-high-risk localized prostate cancer. Patients with ISUP grade group 1 or 2 disease typically see excellent results with standard radiotherapy, making the additional complexity of a focal boost unnecessary. Candidates for this targeted approach include:
- Patients with ISUP grade group 4 or 5 disease.
- Those with T3a, T3b, or T4 N0M0 disease.
- Men with PSA levels exceeding 20 ng/mL.
- Patients with bulky disease or intraductal carcinoma.
The consensus notes that if a tumor occupies more than half of the prostate, the procedure effectively becomes whole-gland dose escalation, losing the specific benefits of a “focal” boost.
How Is the Tumor Target Defined?
Multiparametric MRI is the gold standard for identifying lesions for a focal boost. The ESTRO recommendations mandate the use of T2-weighted MRI and apparent diffusion coefficient imaging for contouring. While PSMA-PET/CT can provide additional context, the panel stopped short of making it a mandatory requirement for every patient due to unresolved questions regarding spatial resolution and uptake thresholds.
If possible, perform MRI imaging before starting androgen deprivation therapy. Hormone therapy can shrink tumors, making them harder to visualize and complicating the definition of the target volume for radiation delivery.
What Are the Emerging Trends in Delivery?
The field is moving toward simultaneous integrated boost (SIB) techniques, which allow the prostate and the focal lesion to be treated during the same session. While conventional fractionation (77 Gy in 35 fractions) remains the standard, researchers are actively studying ultra-hypofractionated radiotherapy. The “hypo-FLAME” trials show promise, but the consensus warns that using fewer than five fractions for a focal boost should currently remain restricted to clinical trials.
How Can Centers Overcome Adoption Barriers?
Widespread adoption of focal boosting faces hurdles, including the need for high-quality MRI access and the technical challenge of MRI-to-CT registration. To succeed, departments must prioritize multidisciplinary imaging reviews and consistent planning procedures. Daily image guidance is not optional; because the prostate moves, clinicians must use protocols that account for both bladder and rectal filling to ensure the high-dose radiation remains locked onto the tumor.
Frequently Asked Questions
Is a focal boost suitable for all prostate cancer patients?
No. According to the ESTRO consensus, it is primarily intended for patients with unfavorable intermediate-risk to very-high-risk disease who have a clearly visible tumor on MRI.
Does a focal boost increase side effects?
When organ-at-risk dose constraints for the rectum, bladder, and urethra are respected, the FLAME trial data indicates that focal boosting does not significantly increase acute or late toxicity.
Is PSMA-PET/CT required for focal boosting?
It is not currently mandatory. The ESTRO panel emphasizes that while it provides useful data, MRI remains the cornerstone for target delineation.
